関連ニュース

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

Crude oil prices surged above $100 as drone attacks forced Saudi Arabia to shut its critical East-West pipeline, threatening up to 4% of global supply. Repair timelines for the Saudi pipeline remain u

Novo Nordisk said it is rebranding its name to "Novo" and updating its corporate culture, as the company works to win back market share in the obesity drug space. The Danish drugmaker called the chan

Canada's new retaliatory tariffs on $20B of U.S. goods escalate trade tensions, impacting North American manufacturers and supply chains. ASML secures commitments from Samsung, TSMC, and Intel for Hig

BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% I

Novo Nordisk A/S NYSE: NVO reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower real

Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, they punished Novo a day earlier – underscoring a growin

SpaceX (SPCX) will deliver its first public earnings report, with focus on Starlink growth, Starship timeline, and capital spending. SPCX shares have fallen over 50% from peak and are 20% below the IP

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO, FRA:1NOR) earlier this week outlined plans for a 2,700-metre reverse circulation drilling program at the...

Wall Street navigated a turbulent week as investors digested the Federal Reserve's latest interest rate decision, a barrage of Big Tech earnings , and renewed geopolitical tensions.

Novo Nordisk shares dive 9% after heart medicine fails trial

The S&P/ASX Small Ordinaries Index (XSO) edged 3.7 points, or 0.11%, higher on Wednesday to close at 3,326.50, although the benchmark remains 44.5 points,...

Novo Nordisk (NVO) is rated a Modest Buy with a raised price target of $80, driven by oral Wegovy's rapid market adoption. Oral Wegovy has achieved over 3 million prescriptions in five months, with 80

I initiate Novo Nordisk with a BUY rating and $68 price target, viewing current valuation as an attractive entry point. Oral Wegovy is expanding the treated obesity market, not just cannibalizing inje

Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That

Eli Lilly and Company, Abbott Laboratories, AbbVie, Novo Nordisk A/S, Pfizer, Bristol Myers Squibb, and Gilead Sciences are the seven Pharmaceutical stocks to watch today, according to MarketBeat's st

Novo Nordisk remains a Buy, supported by favorable catalysts and a resilient long-term bull case. NVO has surged 41% since my previous coverage, outperforming the benchmark's 18% return. Despite a rec